UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies

Biomedicine & pharmacotherapy, 2023-04, Vol.160, p.114392-114392, Article 114392

2023

Volltextzugriff (PDF)

Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs

Biochimica et biophysica acta. Reviews on cancer, 2021-01, Vol.1875 (1), p.188481, Article 188481

Rizzo, Milena

2021

Volltextzugriff (PDF)

Role of chemotherapy in prostate cancer

Asian journal of andrology, 2018-05, Vol.20 (3), p.221-229

2018

Volltextzugriff (PDF)

Bisdemethoxycurcumin Augments Docetaxel Efficacy for Treatment of Prostate Cancer

Biological and Pharmaceutical Bulletin, 2024/08/15, Vol.47(8), pp.1437-1446

2024

Volltextzugriff (PDF)

Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study

BJU international, 2010-10, Vol.106 (7), p.974-978

2010

Volltextzugriff (PDF)

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

Nature biomedical engineering, 2019-04, Vol.3 (4), p.264-280

2019

Volltextzugriff (PDF)

Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice

Anticancer research, 2022-03, Vol.42 (3), p.1465-1475

2022

Volltextzugriff (PDF)

STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel

International journal of molecular sciences, 2023-04, Vol.24 (7), p.6643

2023

Volltextzugriff (PDF)

miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression

The Prostate, 2014-09, Vol.74 (13), p.1320-1334

2014

Volltextzugriff (PDF)

Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

European journal of cancer (1990), 2023-05, Vol.184, p.62-72

2023

Volltextzugriff (PDF)

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m 2 ) and the Currently Approved Dose (25 mg/m 2 ) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA

Journal of clinical oncology, 2017-10, Vol.35 (28), p.3198-3206

2017

Volltextzugriff (PDF)

Gemcitabine–Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel

Bioconjugate chemistry, 2021-12, Vol.32 (12), p.2530-2539

2021

Volltextzugriff (PDF)

Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022

International journal of clinical oncology, 2024-05, Vol.29 (5), p.559-563

2024

Volltextzugriff (PDF)

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer

European journal of cancer (1990), 2024-05, Vol.202, p.114007-114007, Article 114007

2024

Volltextzugriff (PDF)

Evaluation of a docetaxel-cisplatin-fluorouracil-Au complex in human oral carcinoma cell line

Artificial cells, nanomedicine, and biotechnology, 2023-12, Vol.51 (1), p.148-157

2023

Volltextzugriff (PDF)

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2023-08, Vol.182, p.107291-107291, Article 107291

2023

Volltextzugriff (PDF)

Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel

Anticancer research, 2020-01, Vol.40 (1), p.335-339

2020

Volltextzugriff (PDF)

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-10, Vol.373 (17), p.1627-1639

2015

Volltextzugriff (PDF)

Adding carboplatin to chemotherapy regimens for metastatic castrate‐resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes

The Prostate, 2020-10, Vol.80 (14), p.1216-1222

2020

Volltextzugriff (PDF)

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

Journal of clinical oncology, 2017-10, Vol.35 (28), p.3189-3197

2017

Volltextzugriff (PDF)

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

The New England journal of medicine, 2015-08, Vol.373 (8), p.737-746

2015

Volltextzugriff (PDF)

Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)

Cancer, 2024-06, Vol.130 (11), p.1930-1939

2024

Volltextzugriff (PDF)

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

The lancet oncology, 2014-06, Vol.15 (7), p.700-712

2014

Volltextzugriff (PDF)

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

The New England journal of medicine, 2017-03, Vol.376 (11), p.1015-1026

2017

Volltextzugriff (PDF)

Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation

The Prostate, 2016-07, Vol.76 (10), p.927-936

2016

Volltextzugriff (PDF)

1 – 25 von 1.341

Suche als RSS-Feed

Aktive Filter

ThemaTaxoids - Therapeutic Use

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.276)
Mit Volltextzugriff
(1.142)

Publikationsform

Artikel
(1.341)

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(1.302)
Docetaxel
(1.227)
Science & Technology
(1.192)
Life Sciences & Biomedicine
(1.137)
Male
(811)
Oncology
(760)
Antineoplastic Agents - Therapeutic Use
(697)
Female
(638)
Middle Aged
(620)
Aged
(586)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(411)
Chemotherapy
(400)
Treatment Outcome
(384)
Adult
(361)
Taxoids - Administration & Dosage
(357)
Taxoids - Adverse Effects
(353)
Biological And Medical Sciences
(318)
Medical Sciences
(318)
Tumors
(303)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(69)
Cancer Chemotherapy And Pharmacology
(54)
Gan To Kagaku Ryoho
(40)
Anticancer Research
(33)
The Prostate
(27)
Anti-Cancer Drugs
(25)
Cancer
(24)
Lung Cancer
(24)
Plos One
(24)
British Journal Of Cancer
(23)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies

Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs

Role of chemotherapy in prostate cancer

Bisdemethoxycurcumin Augments Docetaxel Efficacy for Treatment of Prostate Cancer

Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice

STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel

miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression

Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m 2 ) and the Currently Approved Dose (25 mg/m 2 ) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA

Gemcitabine–Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel

Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022

A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer

Evaluation of a docetaxel-cisplatin-fluorouracil-Au complex in human oral carcinoma cell line

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer

Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Adding carboplatin to chemotherapy regimens for metastatic castrate‐resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation

Aktive Filter

Suchergebnisse filtern